Eli Lilly and Company LLY NYSE

Eli Lilly and Company (LLY) has shown exceptional revenue growth over the past 3 years, expanding from $28.5B to $65.2B (average +32.1%/yr). Net income reached $20.6B, reflecting exceptional earnings expansion at +60.3%/yr on average. The net profit margin is 31.7%, which is exceptional. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 83.8% (high), with a +7pp trend over the period. With a $872B market cap and MOAT composite score of 100/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (100/100, Pass) — proving strong growth momentum
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 41-year history, the company was profitable in 38 of 41 years — an excellent long-term track record
• INCOME (100/100, Pass) — proves strong profitability and pricing power
• MOAT (100/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 86/100 with 5/7 criteria passed.